"The firm’s technology is called the TCELERATOR platform. Shennon said the platform works by profiling over 10 million single-cell interactions simultaneously and identifies functional leads in a single experiment. This integrated technology engine spans target discovery, ultra-high-throughput microfluidics-driven functional screening, computational binder prediction and optimization, and AI-enabled safety assessment."
“’We’ve now disclosed three T cell engager programs:
• SBT-121, a dual-targeting trispecific antibody-based T cell engager for small cell lung cancer;
• SBT-201, an antibody-based T cell engager for ovarian cancer; and
• SBT-425, a TCR-based T cell engager for hepatocellular carcinoma,’ Cyril Konto told BioXconomy."
"Konto, who will take the reins as CEO, has previously served as CEO at Ichnos Glenmark Innovation and held senior positions at Pfizer and Bristol Myers Squibb. His track record includes leading the development of multiple oncology therapeutics through clinical trials and regulatory approval."
"The latest funding round attracted support from an impressive various investors including Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures, and Saras Capital"
— BioXconomy, Sept 2026
Company: www.ShennonBio.com
Leave a Reply